Belay Announces NCCN Recommendation for CSF-Based Profiling in High-Grade Gliomas
CHICAGO, Ill., June 20, 2026 The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology...
Gastroenterology
Advertisement
cAMPfield Launches With $180M to Advance Oral IBD Therapy
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
Edgewise Reports Positive Phase 2 EDG-7500 HCM Data
BOULDER, Colo., June 16, 2026 Edgewise Therapeutics has announced positive top-line results from the 12-week Phase 2 CIRRUS-HCM trial...
Castle TissueCypher Surpasses 100,000 Orders in Barrett’s
FRIENDSWOOD, Texas, June 16, 2026 Castle Biosciences has announced that its TissueCypher® Barrett’s Esophagus Test has surpassed 100,000 clinical...
Takeda’s ENTYVIO Nears Pediatric IBD FDA Approval
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 9, 2026 Takeda has reached a significant regulatory milestone with the U.S. Food...
Advertisements
Abivax’s Obefazimod Delivers Landmark Phase 3 Success in Ulcerative Colitis
PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...
Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
Abivax Reports Strong Three-Year Remission Results for Obefazimod in Ulcerative Colitis
PARIS, France, May 22, 2026 Abivax announced new three-year interim data from Study 108 showing that obefazimod maintained durable...
Takeda Canada Secures REVESTIVE Reimbursement in BC
TORONTO, ON, Canada – May 5, 2026 Takeda Canada Inc. has announced that REVESTIVE® (teduglutide for injection) will now...
Advertisement
